美敦力BVS 5000：经验与潜在优势。
ABIOMED BVS 5000: experience and potential advantages.
作者信息
Jett G K
机构信息
Department of Cardiothoracic Surgery, Baylor University Medical Center, Dallas, Texas 75218, USA.
出版信息
Ann Thorac Surg. 1996 Jan;61(1):301-4; discussion 311-3. doi: 10.1016/0003-4975(95)01009-2.
BACKGROUND
The ABIOMED BVS 5000 is a two-chambered extracorporeal pulsatile assist device intended for temporary circulatory support. The Food and Drug Administration granted approval for the device for postcardiotomy patients in 1992.
METHODS
A worldwide registry is maintained with the BVS 5000. Currently 500 patients have been entered into the registry. The majority of patients were postcardiotomy (53%) and required biventricular assist devices (65%).
RESULTS
Postcardiotomy patients have had a 27% discharge rate compared with cardiomyopathy patients with a more than 40% discharge rate. Comparison at Baylor University Medical Center of the ABIOMED BVS 5000 with a nonpulsatile device demonstrated an improved wean rate (60% versus 47%, respectively) as well as discharge rate (27% versus 17%, respectively).
CONCLUSIONS
A worldwide registry combined with the experience at Baylor University Medical Center demonstrates the capability of the BVS 5000 to support postcardiotomy patients. The device is safe, simple, and effective. In addition, the pulsatile nature of the circulatory support appears to offer advantages over other systems.
背景
ABIOMED BVS 5000是一种双腔体外搏动辅助装置，旨在提供临时循环支持。1992年，美国食品药品监督管理局批准该装置用于心脏手术后患者。
方法
建立了一个关于BVS 5000的全球注册系统。目前已有500名患者被纳入该注册系统。大多数患者为心脏手术后患者（53%），需要双心室辅助装置（65%）。
结果
心脏手术后患者的出院率为27%，而心肌病患者的出院率超过40%。贝勒大学医学中心对ABIOMED BVS 5000与非搏动装置进行比较，结果显示脱机成功率有所提高（分别为60%和47%），出院率也有所提高（分别为27%和17%）。
结论
全球注册系统结合贝勒大学医学中心的经验表明，BVS 5000有能力支持心脏手术后患者。该装置安全、简单且有效。此外，循环支持的搏动特性似乎比其他系统具有优势。
Zotero 插件